Clearmind Medicine Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Clearmind Medicine Inc. on November 25, 2025, covering the month of November 2025. The filing incorporates a press release announcing the commencement of patient enrollment at Tel Aviv Sourasky Medical Center, a new site for the company's Phase I/IIa clinical trial for Alcohol Use Disorder (AUD).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial progress and does not contain financial statements or quantitative financial data.
Material Changes
The primary material change reported is the activation of an additional clinical trial site in Israel. This expands the operational footprint of the company's Phase I/IIa AUD trial, following the initiation of patient enrollment at the Tel Aviv Sourasky Medical Center.
Outlook and Management Commentary
Management commentary is limited to the operational milestone of starting enrollment at the new site. The filing incorporates "Forward-Looking Statements" from the attached press release, though the specific text of these statements is not included in the provided content. No specific financial guidance or risk factors beyond standard forward-looking language are detailed in the filing text.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific details on the Phase I/IIa trial design and enrollment targets.
- Review the incorporated "Forward-Looking Statements" for specific risks related to clinical trial timelines and regulatory approvals.
- Check subsequent filings for financial updates, as this 6-K contains no financial data.
- Confirm the status of other trial sites to assess the overall pace of the AUD program.